MRI Reveals Distinct ICI-Induced Joint Inflammation Patterns
The whole-body MRI revealed similar inflammation levels in both patients with new arthralgia and those with new inflammatory arthritis after exposure to immune checkpoint inhibitors (ICIs), showing three distinct patterns of inflammation.
METHODOLOGY:
Researchers conducted a prospective imaging study from 2021 to 2024 including 60 patients (mean age, 65 years; 57% men; all White) from regional oncology services at a UK hospital who developed new musculoskeletal symptoms — arthralgia or inflammatory arthritis — after exposure to ICIs.
Those with no history of rheumatologic autoimmune disease, active cancer, or recent joint pain served as healthy control individuals (n = 20; mean age, 62 years; 60% men).
Participants underwent whole-body MRI to assess joint, tendon, bursal, entheseal, and spinal lesions, with imaging patterns analyzed over a 6-month follow-up.
Imaging phenotypes were analyzed, applying a semiquantitative scoring system for synovitis, tenosynovitis, erosions, bursitis, and enthesitis, and compared between patients and healthy individuals.
Scans were categorized into four groups on the basis of imaging patterns: polymyalgia rheumatica, peripheral inflammatory arthritis, spondyloarthropathy, and no specific pattern.
TAKEAWAY:
MRI showed no significant differences between patient groups but showed higher levels of inflammation and erosions in patients with arthralgia and those with inflammatory arthritis than in healthy control individuals, with median joint synovitis scores of 9.0 and 10.0 vs 2.0 and median joint erosion scores of 2.0 for both groups vs 0.0, respectively.
After exposure to ICIs, the commonly affected joints were acromioclavicular (77%), glenohumeral (75%), wrist (73%), and metacarpophalangeal (59%) joints, with knee joint synovitis being more prevalent in patients with inflammatory arthritis than in those with arthralgia (67% vs 29%).
Three distinct MRI patterns were identified: There was a polymyalgia rheumatica pattern in 12% of patients; peripheral inflammatory arthritis pattern in 37% of patients, with varying joint involvement (23% small joints, 32% large joints, and 45% both); and a pattern of overlap of both polymyalgia rheumatica and peripheral inflammatory arthritis in 20%. A total of 31% of patients did not meet any specific pattern criteria.
Four of the five patients who required disease-modifying antirheumatic drugs to manage their symptoms were in the peripheral inflammatory arthritis group.
IN PRACTICE:
'The finding of inflammation and erosions in patients with arthralgia without visible joint swelling suggests that clinical examination is insensitive and that the incidence of joint inflammation induced by immune checkpoint inhibitors is likely to be underestimated,' the experts wrote in a related comment.
SOURCE:
This study was led by Kate Harnden, MB ChB, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, University of Leeds, Leeds, England. It was published online on June 10, 2025, in The Lancet Rheumatology.
LIMITATIONS:
The imaging of feet and ankles was excluded from MRI scans owing to time constraints, which may have overlooked inflammation in those areas. The short follow-up period of 6 months limited the ability to capture long-term outcomes. Including patients with prior autoimmune diseases may have affected the results, and the predefined MRI patterns based on classical arthritis forms may have led to nonspecific pattern labeling.
DISCLOSURES:
This study was supported by the National Institute for Health and Care Research Leeds Biomedical Research Centre. One author reported receiving a bursary travel award, and another was supported by a fellowship program by AbbVie. One author disclosed receiving honoraria, and another received research grants and consulting fees from various sources including Gilead, Lilly, AbbVie, and Deepcare.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Abatacept Beats HCQ in Halting RA in Palindromic Rheumatism
TOPLINE: Abatacept outperformed hydroxychloroquine (HCQ) in preventing patients with palindromic rheumatism (PR) from progressing to rheumatoid arthritis (RA). METHODOLOGY: Researchers randomly assigned 70 individuals with PR who were seropositive for rheumatoid factor or anti-citrullinated protein antibodies in a 1:1 ratio to receive open-label abatacept (ABA) at 125 mg/week or HCQ at 5 mg/kg/day for 1 year. All patients had symptom durations of over 3 months but under 3 years and were not taking any disease-modifying antirheumatic drugs or glucocorticoids. Patients were followed for an additional year to track RA development. TAKEAWAY: At month 24, three patients (8.8%) in the ABA group progressed to RA compared with 10 patients (27.8%) in the HCQ group (P = .047). Patients treated with HCQ who developed RA generally progressed in the first 12 months of the trial, whereas patients treated with ABA who developed RA did so at the end of the second year. The ABA group also had higher persistent remission rates of PR than the HCQ group (55.9% vs 22.9%). Serious adverse events were uncommon in both treatment groups. IN PRACTICE: 'In patients with recent-onset seropositive palindromic rheumatism, abatacept significantly decreased the rate of RA progression in comparison with hydroxychloroquine at 2 years follow-up,' said study author Raimon Sanmarti, MD, PhD, of the Hospital Clínic de Barcelona, Barcelona, Spain. 'Abatacept is also more efficacious than hydroxychloroquine in the control of symptoms of seropositive palindromic rheumatism.' SOURCE: Sanmarti presented the study in an oral abstract session at the European Alliance of Associations for Rheumatology (EULAR) 2025 Annual Meeting. LIMITATIONS: This was an open-label study with a relatively small sample of patients. Over the 2-year trial, eight patients in the HCQ group and five patients in the ABA group exited the trial or were lost to follow-up. DISCLOSURES: The Fundació Clínic per a la Recerca Biomèdica sponsored the study. Sanmarti disclosed financial relationships with Bristol Myers Squibb, AbbVie, MSD, Roche, UCB, Pfizer, Eli Lilly, Gebro, Janssen, Sanofi, Gilead, and Adacyte.
Medscape
an hour ago
- Medscape
MRI May Aid Early Pancreatic Cancer Detection in Diabetes
TOPLINE: MRI-based screening in patients older than 50 years with new-onset or deteriorating diabetes detected stage IB pancreatic cancer in a patient with deteriorating diabetes, highlighting the need for targeted screening in this high-risk population. METHODOLOGY: New-onset diabetes in patients older than 50 years was found to increase the risk for pancreatic cancer by six- to eight-fold, and recent evidence suggests that the deterioration of diabetes in individuals with stable, long-standing disease may also be an indicator of subclinical pancreatic cancer. Researchers conducted the PANDOME study to evaluate the effectiveness and safety of MRI-based screening for the early detection of pancreatic cancer in patients with new-onset diabetes (n = 97; median age, 61 years; 63.9% women) or deteriorating diabetes (n = 12; median age, 68 years; 58.3% women). New-onset diabetes was defined as elevated A1c levels within the past 12 months, whereas deteriorating diabetes was defined as long-standing diabetes (> 2 years) with a > 2% increase in A1c levels over the past 6 months not linked to weight gain or diabetes medication noncompliance. All patients underwent MRI/cholangiopancreatography, blood biobanking, and anxiety/depression monitoring; MRI results were scored as normal, benign-abnormal, suspicious, or incidental findings. TAKEAWAY: Compared with patients with new-onset diabetes, those with deteriorating diabetes had significantly higher A1c levels (P = .02), greater weight loss (P = .0038), and increased insulin requirements (P < .0001). Among 109 participants, more than 50% had small cystic lesions with an average size of 6 mm, prompting seven endoscopic ultrasound procedures — four of which required biopsies. Of the four pancreatic biopsies performed, one revealed stage IB pancreatic ductal adenocarcinoma in a patient with deteriorating diabetes. Extra-pancreatic incidental findings were detected in 8.2% of cases, with two requiring biopsies, revealing one new diagnosis of follicular lymphoma and one diagnosis of recurrent lymphoma. According to the Enriching New-Onset Diabetes for Pancreatic Cancer score — where a high-risk score predicts a 3.6% probability of pancreatic cancer within 3 years — the deteriorating diabetes group had a higher proportion of high-risk individuals than the new-onset diabetes group (75% vs 35.6%). IN PRACTICE: 'Preliminary results from the PANDOME study support further MRI-based PC [pancreatic cancer] screening research efforts in individuals with NOD [new-onset diabetes] and DD [deteriorating diabetes],' the authors concluded. SOURCE: This study was led by Richard Frank, MD, Division of Hematology/Oncology, Nuvance Health, Norwalk, Connecticut. It was published online in The Journal of Clinical Endocrinology & Metabolism. LIMITATIONS: T his study faced challenges with low accrual rates due to healthcare network realignments and high declination rates by potential participants. Selection bias potentially led to lower detection rates, as most participants were referred by primary care physicians or endocrinologists. Moreover, the majority of participants were White individuals (83%), despite higher pancreatic cancer risk among Black populations, limiting generalizability. DISCLOSURES: This study received support from a Tribute to Pamela/The Naughton Family Fund, the Rallye for Pancreatic Cancer, Pacific Crest Trail for Pancreatic Cancer, and the Glenn W. Bailey Foundation. The authors declared no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Washington Post
an hour ago
- Washington Post
At Wimbledon, a player's lament about loneliness revives a conversation about mental health
LONDON — When Naomi Osaka opened up about her anxiety and depression at the 2021 French Open, it sparked a conversation in sports — and society at large — about mental health and the importance of addressing such issues. In the time since, more and more players have spoken about the topic and seeking help, and whatever taboos there were seem to have faded. Still, the way three-time Grand Slam finalist Alexander Zverev discussed his state of mind after a first-round exit at Wimbledon this week revived the conversation.
